Tag: obligation

WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today announced its top-line revenue forecast for its specialty care pipeline, projecting nearly $1 billion in revenue in its launch year and a cumulative 5-year estimate of between $18 billion and $22 billion. This forecast reflects the company’s unique, faster, and cost-efficient drug development model which has the potential to serve as a blueprint to ensure sustainable medical innovation for years to come.

DARIEN, Conn., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Carronade Capital Management, LP on behalf of its managed entities (“Carronade Capital”, “our” or “we”), which beneficially own approximately 3.2 million shares of Common Stock of Cannae Holdings, Inc. (NYSE: CNNE) (“Cannae” or the “Company”) and is one of the Company’s top shareholders, today posed important questions that it believes shareholders would like to see answered by Cannae’s executive team during its second quarter 2025 earnings call scheduled for 5:00 pm ET on August 11, 2025.

WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today released a letter to stockholders.

DALLAS, Aug. 11, 2025 (GLOBE NEWSWIRE) -- HF Sinclair Corporation (NYSE and NYSE Texas: DINO) (the “Corporation”) today announced that it has commenced a cash tender offer (the “Tender Offer”) to purchase any and all of the outstanding notes listed in the table below (collectively, the “Notes” and each a “Series” of Notes).

Strategic appointment strengthens Actelis' commercialization efforts and focus across Federal/Military/Local Gov. and telecommunications markets with proven sales leader bringing over 30 years of experience in defense, government, and carrier sectors